Trending...
- All American Home Renovators: Transforming Bathrooms into Masterpieces, One Home at a Time
- Contracting Resources Group Named to the 2026 Inc. Regionals: Mid-Atlantic List
- LLM Classroom Launches AI Prompt Packs for Business Professionals
CHICAGO, June 22, 2025 ~ A recent study has revealed that oral semaglutide, a medication used to treat type 2 diabetes, can significantly reduce the risk of cardiovascular events by 14%. The results were presented at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago as a late-breaking symposium.
The study, known as the Semaglutide Cardiovascular Outcomes Trial (SOUL), focused on adults with type 2 diabetes who are at a higher risk for cardiovascular disease. It is well-known that individuals with diabetes have a 2-4 times increased risk of developing heart disease compared to those without diabetes. This risk increases with poor glycemic control and can lead to serious conditions such as heart attacks, stroke, and heart failure.
One of the major benefits of oral semaglutide is that it eliminates the need for injections, making it more convenient for patients and potentially improving adherence to treatment. This could also lead to earlier initiation of therapy and provide cardiovascular protection for patients who may have been hesitant to use injectable medications.
More on illi News
The double-blind, placebo-controlled trial included 9,650 participants aged 50 or older with type 2 diabetes and an A1C level between 6.5% and 10.0%. All participants had either known atherosclerotic cardiovascular disease or chronic kidney disease, or both. They were randomly assigned to receive either once-daily oral semaglutide or a placebo in addition to standard care.
The primary outcome of the study was major adverse cardiovascular events (MACE), which includes death from cardiovascular causes, nonfatal myocardial infarction (heart attack), or nonfatal stroke. The results showed that there was a significant reduction in MACE among those taking oral semaglutide compared to those taking the placebo. The incidence of serious adverse events was similar between the two groups.
Dr. Darren K. McGuire, lead author of the study and a professor of medicine at UT Southwestern Medical Center, emphasized the importance of addressing co-morbidities such as heart disease when treating patients with type 2 diabetes. He believes that the findings of this study suggest that oral semaglutide could be a promising option for patients in need of treatment for both diabetes and cardiovascular risk.
More on illi News
The initial results of the study were published in the New England Journal of Medicine in March, showing a 14% reduction in MACE. The new results presented at the ADA's Scientific Sessions will provide further insight into these findings.
Dr. McGuire will present the full results during a symposium presentation on Sunday, June 22 at 4:30 PM CT. The presentation is titled "Effects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk." The researchers also plan to implement these findings in a real-world setting to better inform clinical next steps.
This study highlights the potential benefits of oral semaglutide for individuals with type 2 diabetes who are at high risk for cardiovascular disease. It offers hope for improved outcomes and better management of this chronic condition.
The study, known as the Semaglutide Cardiovascular Outcomes Trial (SOUL), focused on adults with type 2 diabetes who are at a higher risk for cardiovascular disease. It is well-known that individuals with diabetes have a 2-4 times increased risk of developing heart disease compared to those without diabetes. This risk increases with poor glycemic control and can lead to serious conditions such as heart attacks, stroke, and heart failure.
One of the major benefits of oral semaglutide is that it eliminates the need for injections, making it more convenient for patients and potentially improving adherence to treatment. This could also lead to earlier initiation of therapy and provide cardiovascular protection for patients who may have been hesitant to use injectable medications.
More on illi News
- Evermore Bliss Launches AI Wedding Speech Writer to Help Users Create Personalized, Heartfelt Toasts
- 5th Annual Chicago Scavenger Hunt June 13 & 14
- Keenethics enters the ChatGPT Apps ecosystem as a new growth opportunity for businesses
- Spring Into Your New Home at Heritage at South Brunswick
- Naperville: Downtown Parking Garage Maintenance Work Begins on April 20
The double-blind, placebo-controlled trial included 9,650 participants aged 50 or older with type 2 diabetes and an A1C level between 6.5% and 10.0%. All participants had either known atherosclerotic cardiovascular disease or chronic kidney disease, or both. They were randomly assigned to receive either once-daily oral semaglutide or a placebo in addition to standard care.
The primary outcome of the study was major adverse cardiovascular events (MACE), which includes death from cardiovascular causes, nonfatal myocardial infarction (heart attack), or nonfatal stroke. The results showed that there was a significant reduction in MACE among those taking oral semaglutide compared to those taking the placebo. The incidence of serious adverse events was similar between the two groups.
Dr. Darren K. McGuire, lead author of the study and a professor of medicine at UT Southwestern Medical Center, emphasized the importance of addressing co-morbidities such as heart disease when treating patients with type 2 diabetes. He believes that the findings of this study suggest that oral semaglutide could be a promising option for patients in need of treatment for both diabetes and cardiovascular risk.
More on illi News
- UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
- HarryPotterObamaSonic10Inu (Ticker: BITCOIN) Is the Best Cryptocurrency in Global History
- Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
- GitKraken Desktop 12.0 Introduces Agent Mode: Gives Developers Ultimate Control & Visualization While Scaling Parallel Agent Workflows
- 5 Things to Check Before Calling for AC Repair in Philly
The initial results of the study were published in the New England Journal of Medicine in March, showing a 14% reduction in MACE. The new results presented at the ADA's Scientific Sessions will provide further insight into these findings.
Dr. McGuire will present the full results during a symposium presentation on Sunday, June 22 at 4:30 PM CT. The presentation is titled "Effects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk." The researchers also plan to implement these findings in a real-world setting to better inform clinical next steps.
This study highlights the potential benefits of oral semaglutide for individuals with type 2 diabetes who are at high risk for cardiovascular disease. It offers hope for improved outcomes and better management of this chronic condition.
Filed Under: Business
0 Comments
Latest on illi News
- Beverly.io Announces Nationwide Expansion and Poppins Payroll Partnership for Families
- Mayor Brandon Johnson, Chicago Department of Public Health Announce 50% Decline in Overdose Deaths Among Black Women, Marking the Start of Black Maternal Health Week in Chicago
- New Book: The Battle for Truth and Shadows - Guardians of Light - Epic Fantasy Unveils a War Between Light and Deception
- Chicago: O'Hare International Airport Reclaims Title of Busiest Airfield in The World
- Clash of Prompts: The World's First AI Prompt Battle Royale
- $7.6 Billion US Crypto ATM Market by 2034; California and Texas Crypto ATM Deployments for Bitcoin Bancorp (Stock Symbol: BCBC); 1000 Kiosk Inventory
- MainConcept Announces Multiview Encoding for Apple Immersive Video
- CCHR Rejects Global Psychiatric Push to Electroshock Children
- iVAM2-ST2110 to Simplify IP Transitions and Reduce Monitoring Complexity
- Americans Leave Behind or Discard 42% of Their Belongings When Moving Out for the First Time, Talker Research Finds
- Central Florida Luxury Real Estate Firm DANHOLM COLLECTION Partners with Luxury Presence to Expand Global Buyer Reach
- Advantage Marketing Launches 3-Minute Assessment to Help SMBs Diagnose and Fix Marketing Gaps
- Chris The Wiz Releases AIRINCRAD EP
- InterMountain Management Announces the Re-opening of Holiday Inn Express & Suites Alexandria
- New Slide-On Ear Cover Concept Enhances Cold Weather Comfort for Cap Wearers
- Naperville Police Investigate Alleged Home Invasion
- Midwest Pond Features & Landscape Highlights April as Critical Month for Pond Maintenance
- Mayor Brandon Johnson, Department of Family and Support Services, And Chicago Early Learning to Celebrate The Month of the Young Child with Sold-out, First-ever "Chicago's Largest Playdate" At Maggie Daley Park
- Chicago: Mayor Brandon Johnson, Mayor's Office for People with Disabilities Host Summer Jobs Hiring Fair for Students and Young Adults with Disabilities
- CB Stuffer Expands New England Footprint with Launch at Common Man Roadside in Hooksett, NH